Obesity Pillars
Orforglipron linked to weight loss in a trial subgroup
Orforglipron at 17.2 mg daily was associated with 13.5% average weight loss over 72 weeks, versus 0.3% with placebo.Orforglipron at 17.2 mg daily was associated with 13.5% average weight loss over 72 weeks, versus 0.3% with placebo.
Randomized trial · 260 peopleOrforglipron
Who was studied260 adults with overweight and adiposity-related complications, against placebo
What changedAverage body weight fell 13.5% with orforglipron at 17.2 mg daily, versus 0.3% with placebo over 72 weeks
The catchResearchers examined this subgroup after the original trial, rather than designing the trial for it